UNION therapeutics A/S, a Denmark-based, privately held, clinical stage, pharmaceutical development company, on Wednesday announced results from the ADESOS Phase 2b study with orismilast in adults with moderate to severe atopic dermatitis.

The results were presented by Prof Dr Eric Simpson at the EADV Congress 2024.

Data from the 233 patients randomised and dosed in the study demonstrated that significantly more patients achieved Investigator Global Assessment (IGA) 0/1 responses at Week 16 in the orismilast 20mg, 30mg and 40mg groups, compared to placebo. Additionally, the efficacy observed using the IGA score was supported by changes in skin levels of TARC (CCL17/thymus and activation-regulated chemokine), a key disease biomarker of AD. Data showed that TARC skin levels were significantly reduced in the active arms, with end of treatment levels approaching those of non-lesional skin.

Kim Kjoller, UNION co-CEO, said: "The results from the ADESOS study with orismilast in atopic dermatitis (AD) follows positive readouts in psoriasis and hidradenitis suppurativa (HS) confirming the potential of orismilast as a safe oral treatment option across immunology. We are excited that the results have been presented today as a late-breaking oral presentation by Prof. Dr. Eric Simpson at the EADV Congress 2024. It is always a pleasure being at the conference and discussing the results with leading experts within the field as we plan to progress orismilast to Phase 3 development in atopic dermatitis."